Findings

What do systematic reviews say?

970 questions · 979 findings · 135 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 182 · 18.6%GRADE not reported 84 · 8.6%Very low 165 · 16.9%Low 311 · 31.8%Moderate 163 · 16.6%High 74 · 7.6%

BNT162b2 – Pfizer/BioNTech + Fosun Pharma vs placebo

Systemic reactogenicity events

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gam‐COVID‐VAC – Sputnik V vs placebo

Severe or critical COVID‐19

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19866 participants
Moderate

Gam‐COVID‐VAC – Sputnik V vs placebo

All‐cause mortalityf

It is very uncertain whether gam‐COVID‐VAC – Sputnik V changes all‐cause mortalityf compared with placebo (very low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.99 [0.1, 9.54]
1 study · 21862 participants
Very low

Gam‐COVID‐VAC – Sputnik V vs placebo

Systemic reactogenicity events

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gam‐COVID‐VAC – Sputnik V vs placebo

Any adverse event

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gam‐COVID‐VAC – Sputnik V vs placebo

Serious adverse eventsf

Gam‐COVID‐VAC – Sputnik V showed no clear difference in serious adverse eventsf compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.65 [0.39, 1.07]
1 study · 21862 participants
Low

Gam‐COVID‐VAC – Sputnik V vs placebo

Local reactogenicity events

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CoronaVac – Sinovac vs placebo

Confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CoronaVac – Sinovac vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 19852 participants
Low

CoronaVac – Sinovac vs placebo

Severe or critical COVID‐19

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 19852 participants
Low

CoronaVac – Sinovac vs placebo

All‐cause mortalityh

CoronaVac – Sinovac showed no clear difference in all‐cause mortalityh compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.5 [0.05, 5.52]
2 studies · 22610 participants
Low

BNT162b2 – Pfizer/BioNTech + Fosun Pharma vs placebo

Any adverse eventi

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 46149 participants
Low

CoronaVac – Sinovac vs placebo

Systemic reactogenicity events

CoronaVac – Sinovac showed no clear difference in systemic reactogenicity eventsj compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.19 [1, 1.42]
6 studies · 23966 participants
Low

CoronaVac – Sinovac vs placebo

Any adverse evento

CoronaVac – Sinovac leads to higher any adverse evento compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.09 [1.07, 1.11]
6 studies · 23367 participants
High

CoronaVac – Sinovac vs placebo

Serious adverse eventsr

CoronaVac – Sinovac showed no clear difference in serious adverse eventsr compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.97 [0.62, 1.51]
4 studies · 23139 participants
Low

CoronaVac – Sinovac vs placebo

Local reactogenicity events

CoronaVac – Sinovac leads to higher local reactogenicity eventsj compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.76 [1.69, 1.82]
6 studies · 23962 participants
High

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25449 participants
High

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25480 participants
High

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Severe or critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

All‐cause mortalityÂ

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found